NASDAQ: HOLX | Healthcare / Medical Devices & Instruments / USA |
72.99 | +0.9200 | +1.28% | Vol 655.10K | 1Y Perf -6.17% |
Aug 12th, 2022 16:00 DELAYED |
BID | 72.93 | ASK | 73.05 | ||
Open | 72.27 | Previous Close | 72.07 | ||
Pre-Market | - | After-Market | 72.91 | ||
- - | -0.08 -0.11% |
Target Price | 79.60 | Analyst Rating | Moderate Buy 2.25 | |
Potential % | 9.06 | Finscreener Ranking | ★★★+ 52.50 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 56.13 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 67.47 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 44.33 | Earnings Rating | Neutral | |
Market Cap | 18.22B | Earnings Date | 27th Jul 2022 | |
Alpha | 0.00 | Standard Deviation | 0.10 | |
Beta | 1.09 |
Today's Price Range 72.0373.02 | 52W Range 66.5881.04 | 5 Year PE Ratio Range -91.4040.30 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 2.23% | ||
1 Month | 3.75% | ||
3 Months | -4.31% | ||
6 Months | 1.39% | ||
1 Year | -6.17% | ||
3 Years | 45.02% | ||
5 Years | 91.07% | ||
10 Years | 267.15% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 20.73 | |||
ROE last 12 Months | 35.90 | |||
ROA (5Y Avg) | 6.16 | |||
ROA last 12 Months | 17.84 | |||
ROC (5Y Avg) | 12.73 | |||
ROC last 12 Months | 21.34 | |||
Return on invested Capital Q | 3.14 | |||
Return on invested Capital Y | 29.43 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 6.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
12.20 | ||||
3.60 | ||||
3.44 | ||||
7.60 | ||||
8.50 | ||||
9.50 | ||||
65.31 | ||||
20.02 | ||||
18.46B | ||||
Forward PE | 19.66 | |||
PEG | 0.81 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.10 | ||||
3.90 | ||||
0.36 | ||||
0.57 | ||||
20.80 | ||||
Leverage Ratio | 2.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
63.40 | ||||
37.30 | ||||
45.70 | ||||
18.60 | ||||
29.00 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.23B | ||||
20.93 | ||||
18.32 | ||||
12.95 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2022 | 0.69 | 0.95 | 37.68 |
Q02 2022 | 1.55 | 2.07 | 33.55 |
Q01 2022 | 1.20 | 2.17 | 80.83 |
Q04 2021 | 0.98 | 1.61 | 64.29 |
Q03 2021 | 1.11 | 1.33 | 19.82 |
Q02 2021 | 2.62 | 2.59 | -1.14 |
Q01 2021 | 2.14 | 2.86 | 33.64 |
Q04 2020 | 1.22 | 2.07 | 69.67 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.69 | -4.17 | Negative |
9/2022 QR | 0.63 | -13.70 | Negative |
9/2022 FY | 5.54 | 8.63 | Positive |
9/2023 FY | 3.63 | -3.46 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 0.69 |
Estimates Count | 6 |
EPS Growth Next 5 Years % | 14.40 |
Volume Overview | |
---|---|
Volume | 655.10K |
Shares Outstanding | 249.65K |
Shares Float | 180.83M |
Trades Count | 13.49K |
Dollar Volume | 47.67M |
Avg. Volume | 1.46M |
Avg. Weekly Volume | 1.13M |
Avg. Monthly Volume | 1.52M |
Avg. Quarterly Volume | 1.73M |
Hologic Inc. (NASDAQ: HOLX) stock closed at 72.99 per share at the end of the most recent trading day (a 1.28% change compared to the prior day closing price) with a volume of 655.10K shares and market capitalization of 18.22B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 5814 people. Hologic Inc. CEO is Stephen P. Macmillan.
The one-year performance of Hologic Inc. stock is -6.17%, while year-to-date (YTD) performance is -4.66%. HOLX stock has a five-year performance of 91.07%. Its 52-week range is between 66.58 and 81.04, which gives HOLX stock a 52-week price range ratio of 44.33%
Hologic Inc. currently has a PE ratio of 12.20, a price-to-book (PB) ratio of 3.60, a price-to-sale (PS) ratio of 3.44, a price to cashflow ratio of 7.60, a PEG ratio of 2.32, a ROA of 17.84%, a ROC of 21.34% and a ROE of 35.90%. The company’s profit margin is 29.00%, its EBITDA margin is 45.70%, and its revenue ttm is $5.23 Billion , which makes it $20.93 revenue per share.
Of the last four earnings reports from Hologic Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.69 for the next earnings report. Hologic Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Hologic Inc. is Moderate Buy (2.25), with a target price of $79.6, which is +9.06% compared to the current price. The earnings rating for Hologic Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Hologic Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Hologic Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.58, ATR14 : 1.69, CCI20 : 127.85, Chaikin Money Flow : 0.26, MACD : 0.38, Money Flow Index : 52.56, ROC : 2.89, RSI : 45.94, STOCH (14,3) : 93.74, STOCH RSI : 1.00, UO : 51.95, Williams %R : -6.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Hologic Inc. in the last 12-months were: Benjamin J. Cohn (Option Excercise at a value of $434 798), Benjamin J. Cohn (Sold 15 644 shares of value $1 191 450 ), Jan Verstreken (Sold 6 500 shares of value $512 168 ), Sean S. Daugherty (Sold 2 179 shares of value $155 016 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
CEO: Stephen P. Macmillan
Telephone: +1 508 263-2900
Address: 250 Campus Drive, Marlborough 01752, MA, US
Number of employees: 5 814
Fri, 29 Jul 2022 05:27 GMT Analysts Offer Insights on Healthcare Companies: Hologic (HOLX) and Myovant Sciences (MYOV)
- TipRanks. All rights reserved.Thu, 28 Jul 2022 09:55 GMT Hologic (HOLX) Gets a Hold Rating from Needham
- TipRanks. All rights reserved.Tue, 17 May 2022 12:40 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX), Select Medical (SEM) and Bluebird Bio (BLUE)
- TipRanks. All rights reserved.Thu, 28 Apr 2022 10:25 GMT Analysts Conflicted on These Healthcare Names: Hologic (HOLX), Viking Therapeutics (VKTX) and Aslan Pharmaceuticals (ASLN)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.